Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bellerophon Pulse Technologies
An open-label, long-term study to evaluate the safety of inhaled nitric oxide (iNO) in subjects with pulmonary arterial hypertension (PAH) who participated in IK-7001-PAH-201 and PULSE-PAH-004 to provide these patients with continued access to chronic iNO until the time of approval or development of iNO in PAH is discontinued.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed Informed Consent Form prior to the initiation of any study mandated procedures or assessments.
PAH subjects who have completed all EOS assessments in IK-7001-PAH-201 and PULSE-PAH-004 and have continued drug/device usage.
Subjects are willing and considered in the judgement of the Investigator able to use the INOpulse device continuously for up to 24 hours per day.
All female subjects must be willing to continue to take adequate precaution to avoid pregnancy.
Subjects in need for continued treatment with iNO in the opinion of the treating physician and agreement from Sponsor.
You may not be if
Subjects who require treatment with riociguat
Subjects who early discontinued drug/device usage due to withdrawal of consent or an AE requiring termination from treatment in IK-7001-PAH-201
Clareo Health | Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH
